Process Technology (Ultrafiltration, Microfiltration, Nanofiltration), Application (Pharmaceutical Filtration, Hemodialysis, ...

Sibeprenlimab, a monoclonal antibody, is the only IgA nephropathy treatment option to selectively inhibit the activity of a ...

IV drips for hangovers are becoming a flashy trend, but experts warn they may strain vital organs. While they might look ...

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.

Many people carry elevated uric acid for years without too much pain, until a gout attack or a kidney stone forces a doctor’s ...

Otsuka Pharmaceutical has accelerated FDA approval for Voyxact to reduce proteinuria in adults with primary IgAN at disease ...

An adequate intake of water helps prevent dehydration, supports kidney function, and aids in reducing high blood sugar levels.

Otsuka receives US FDA accelerated approval for Voyxact to reduce proteinuria in adults with IgAN: Princeton, New Jersey Thursday, November 27, 2025, 12:00 Hrs [IST] Otsuka Pharma ...

Explore how lab report reference ranges shape our understanding of health, emphasizing the complexity behind the concept of ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today announce the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ...

This acceptance follows Sangamo’s meeting with the FDA in October 2025 to discuss the proposed efficacy and safety data package for isaralgagene civaparvovec where, in the meeting minutes, among other ...

Both type 1 and type 2 diabetes can cause chronic kidney disease. However, type 2 diabetes is much more common and therefore ...